Skip to main content
Equibles

MSCL · Satellos Bioscience Inc.

Use MSCL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MSCL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
10.1200 CAD +1.1000 (+12.20%) At close · Nov 6 Intraday price with Plus
Rebalance outlook locked

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close10.1200 CAD Open9.4000 CAD Day9.2000–10.4900 CAD Since split7.8900–17.8500 CAD Avg vol 30d11K Last earningsJul 8, 2026 DataJan 2026–Nov 2026

Raw chart and full-history price indicators begin at the captured split on Jan 30, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Jan 30, 2026.

Latest documents

2026
Nov 6
Current report 6-K
BASECAMP switches to MRI fat-fraction endpoint after FDA feedback

Satellos Bioscience Inc. changed BASECAMP’s primary efficacy endpoint following FDA feedback to change in vastus lateralis fat fraction measured by MRI, replacing dynamometry. Topline 12-week placebo-controlled data are expected in Q1 2027.

2 source passages
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially life-improving medicines to treat degenerative muscle disorders, today announced that, following feedback from the U.S. Food and Drug Administration (FDA), it has selected change in vastus lateralis fat fraction measured by magnetic resonance imaging (MRI) as the primary efficacy endpoint in the BASECAMP Phase 2 clinical study in boys ages 7, 8 or 9 with Duchenne muscular dystrophy (DMD). Change in MRI-measured fat fraction will replace dynamometry as the study’s primary efficacy endpoint. Topline 12-week placebo-controlled BASECAMP data expected in Q1 2027 Open the document at this passage
Oct 27
Current report 6-K
Current report

Satellos Bioscience Inc. formed a Scientific Advisory Board to guide research into regeneration, aging and neurodegenerative biology, with Janet Rossant serving as chair. The board will advise on stem cell biology, molecular signaling and disease pathology.

All documents

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its range since split · 2026-01-30
Range low 7.8900 CAD Now 10.1200 CAD · 22% Range high 17.8500 CAD
vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

Raw-price comparisons begin at the captured split on Jan 30, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
XTSE:MSCL +6.1% -2.9% +1.7% +6.1% —

Exchange listing

Market
XTSE
Ticker
MSCL
ISIN
—
Security
Ordinary share
Trading currency
CAD

Company with tickers: MSLE

Company

Website
https://satellos.com/
Investor relations
https://ir.satellos.com/overview/default.aspx

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Latest price

Plus & Pro

Follow MSCL during the session: the latest price, the day's change, range and volume. Closing prices stay free.

View plans Sign in

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

DateEventType
2026-11-09 14:30 UTC Guggenheim 3rd Annual Healthcare Innovation Conference Conference
2026-11-18 00:00 UTC Jefferies Global Healthcare Conference Conference

Earnings calls

  • Conference · November 2026 2026-11-18 Scheduled
    Jefferies Global Healthcare Conference
  • Conference · November 2026 2026-11-09 Scheduled
    Guggenheim 3rd Annual Healthcare Innovation Conference
  • Conference · September 2026 2026-09-16 Audio Transcript
    H.C. Wainwright 28th Annual Global Investment Conference
  • Earnings call · Q2 2026 2026-07-08 Audio Transcript
    Earnings conference call (announced in 6-K)
  • Conference · June 2026 2026-06-02 Audio Transcript
    Jefferies Global Healthcare Conference
  • Conference · April 2026 2026-04-21 Audio Transcript
    2026 Bloom Burton & Co. Healthcare Investor Conference
  • Conference · March 2026 2026-03-08
    2026 Muscular Dystrophy Association Clinical & Scientific Conference
  • Investor Update · February 2026 2026-02-24
    Satellos KOL Event - Unmet need and evolving treatment landscape in Duchenne muscular dystrophy